Synairgen, a respiratory drug discovery and development company, has reported positive results in its COVID-19 clinical trial. Of the participants who received the investigational drug SNG001, 79% had a lower risk of developing severe disease than compared with those that were given a placebo. The trial involved 101 participants and took place in the United Kingdom. With 21 strategically located global depots, including a 7,730 square foot regional depot in Heathrow, London, Yourway has the capacity to service companies in need of clinical trial support around the world.